Journal
DRUGS
Volume 69, Issue 3, Pages 241-249Publisher
ADIS INT LTD
DOI: 10.2165/00003495-200969030-00001
Keywords
-
Categories
Funding
- American Association of Neurological Surgeons Neurosurgery Research and Education Foundation
- University of Wisconsin-Madison, Madison, WI, USA
Ask authors/readers for more resources
Despite the many overall advances in understanding cancer biology and therapeutic development in the last 50 years, most CNS malignancies are still clinically difficult, incurable diseases. Current combinations of aggressive surgical resection, radiation therapy and chemotherapy regimens do not significantly improve long-term patient survival for these cancers. Cancer immunotherapy is a potentially promising new therapeutic strategy that primes a patient's immune system to attack neoplastic cells. We review the preclinical and clinical progress in developing vaccination-based therapy for CNS malignancies to date, including peptide-based vaccinations, dendritic cell-based vaccinations and other potential modalities. Some of the challenges for developing an effective vaccination strategy, such as abnormal immune molecules on glioma cells and abnormal lymphocyte populations within a glioma, are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available